Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates in two segments, EVT Execute and EVT Innovate. The EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services. The EVT Innovate segment is involved in investing and developing proprietary assets, including early-stage discovery programs, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. Evotec AG has a strategic drug discovery and development partnership with Celgene Corporation; strategic research alliance with Novo Nordisk A/S; collaboration with Sanofi; research collaboration with Almirall; research alliance with Ferring Pharmaceuticals; strategic collaboration with Centogene; collaboration with Immuneering; and drug discovery alliance with LEO Pharma. The company was founded in 1993 and is headquartered in Hamburg, Germany.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone49-4056-0810
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$443.55 million
Profitability
Miscellaneous
Employees2,178
Next Earnings Date8/8/2019 (Estimated)
OptionableNot Optionable
Evotec (OTCMKTS:EVTCY) Frequently Asked Questions
What is Evotec's stock symbol?
Evotec trades on the OTCMKTS under the ticker symbol "EVTCY."
How were Evotec's earnings last quarter?
Evotec AG (OTCMKTS:EVTCY) issued its quarterly earnings data on Tuesday, May, 14th. The company reported $0.20 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.18 by $0.02. The firm earned $118.01 million during the quarter. Evotec had a return on equity of 21.56% and a net margin of 23.40%. View Evotec's Earnings History.
When is Evotec's next earnings date?
What is the consensus analysts' recommendation for Evotec?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evotec in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Evotec.
Has Evotec been receiving favorable news coverage?
Press coverage about EVTCY stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Evotec earned a daily sentiment score of 0.7 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an impact on the company's share price in the immediate future.
Who are some of Evotec's key competitors?
Some companies that are related to Evotec include GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GNMSF), Mylan (MYL), Ionis Pharmaceuticals (IONS), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), SAGE Therapeutics (SAGE), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Loxo Oncology (LOXO), Marina Biotech (MRNA) and Perrigo (PRGO).
What other stocks do shareholders of Evotec own?
Who are Evotec's key executives?
Evotec's management team includes the folowing people:
- Dr. Werner Lanthaler, CEO & Member of Management Board (Age 51)
- Mr. Enno Spillner, CFO & Member of Management Board (Age 49)
- Dr. Cord Dohrmann, Chief Scientific Officer & Member of Management Board (Age 55)
- Dr. Craig Johnstone, COO & Member of Management Board
- Ms. Anja Bosler, Principal Accounting Officer and Sr. VP of Group Accounting
How do I buy shares of Evotec?
Shares of EVTCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Evotec's stock price today?
One share of EVTCY stock can currently be purchased for approximately $51.86.
How big of a company is Evotec?
Evotec has a market capitalization of $3.84 billion and generates $443.55 million in revenue each year. The company earns $99.45 million in net income (profit) each year or $1.32 on an earnings per share basis. Evotec employs 2,178 workers across the globe.
What is Evotec's official website?
How can I contact Evotec?
Evotec's mailing address is Manfred Eigen Campus Essener Bogen 7, Hamburg 2M, 22419. The company can be reached via phone at 49-4056-0810 or via email at [email protected]
MarketBeat Community Rating for Evotec (OTCMKTS EVTCY)
MarketBeat's community ratings are surveys of what our community members think about Evotec and other stocks. Vote "Outperform" if you believe EVTCY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVTCY will underperform the S&P 500 over the long term. You may vote once every thirty days.
